Coriorretinopatía central serosa

Ignacio Balparda; Daniel Colombero

doi:10.70313/2718.7446.v17.n03.342

Autores/as

Ignacio Balparda Hospital Provincial del Centenario
Daniel Colombero Hospital Provincial del Centenario, Rosario, Argentina

DOI:

https://doi.org/10.70313/2718.7446.v17.n03.342

Palabras clave:

coriorretinopatía central serosa, terapia con láser de micropulsos, terapia fotodinámica con verteporfina

Resumen

La coriorretinopatía central serosa es una patología ocular que afecta la mácula, se caracteriza por la acumulación de líquido subretinal y puede afectar la visión central y, de este modo, también modificar la calidad de vida de los pacientes. Se da por una descompensación en el epitelio pigmentario de la retina y cambios vasculares coroideos. Es una causa frecuente de pérdida de visión central que afecta principalmente a hombres de 20 a 60 años.

Hasta la fecha, no se ha llegado a un consenso sobre su clasificación y se ha propuesto una amplia variedad de intervenciones, lo que refleja la controversia asociada al tratamiento de esta enfermedad. La reciente publicación de ensayos controlados aleatorizados con un poder estadístico adecuado, así como grandes estudios retrospectivos no aleatorizados sobre su tratamiento, sugieren la viabilidad de un enfoque basado en la evidencia a la hora de considerar las opciones terapéuticas.

Se ha reportado la eficacia de muchas estrategias de tratamiento, como la terapia fotodinámica con verteporfina, los antagonistas de mineralocorticoides orales y el tratamiento con láser de micropulsos. Sin embargo, las pruebas disponibles actualmente sugieren que la terapia con láser de micropulsos y la terapia fotodinámica deberían ser el tratamiento de elección en la coriorretinopatía crónica, mientras que la conducta expectante puede ser el enfoque preferido en su manifestación aguda. No obstante, pueden considerarse excepciones en función de las características específicas de cada paciente.

Citas

Gupta A, Tripathy K. Central serous chorioretinopathy. En: StatPearls [en línea]. Treasure Island (FL): StatPearls Publishing, 2023 Aug. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK558973/

Fung AT, Yang Y, Kam AW. Central serous chorioretinopathy: a review. Clin Exp Ophthalmol 2023; 51: 243-270.

Park JB, Kim K, Kang MS et al. Central serous chorioretinopathy: treatment. Taiwan J Ophthalmol 2022; 12: 394-408.

Ivanišević M, Stanić R, Ivanišević P, Vuković A. Albrecht von Graefe (1828-1870) and his contributions to the development of ophthalmology. Int Ophthalmol 2020; 40: 1029-1033.

Rosen E. Central serous retinopathy. Am J Ophthalmol 1948; 31: 734.

Bennett G. Central serous retinopathy. Br J Ophthalmol 1955; 39: 605-618.

Kitzmann AS, Pulido JS, Diehl NN et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology 2008; 115: 169-173.

Facello Olmedo FM, Ormaechea G. Coriorretinopatía serosa central aguda y crónica: cambios coroideos observados con tomografía de coherencia óptica con imagen de profundidad mejorada. Oftalmol Clin Exp 2021; 14: 71-80.

Daruich A, Matet A, Dirani A et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 2015; 48: 82-118.

Daruich A, Matet A, Marchionno L et al. Acute central serous chorioretinopathy: factors influencing episode duration. Retina 2017; 37: 1905-1915.

Ficker L, Vafidis G, While A, Leaver P. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1988; 72: 829-834.

Gerendas BS, Kroisamer JS, Buehl W et al. Correlation between morphological characteristics in spectral-domain-optical coherence tomography, different functional tests and a patient's subjective handicap in acute central serous chorioretinopathy. Acta Ophthalmol 2018; 96: e776-e782.

Wang M, Munch IC, Hasler PW et al. Central serous chorioretinopathy. Acta Ophthalmol 2008; 86: 126-145.

Yannuzzi NA, Mrejen S, Capuano V et al. A central hyporeflective subretinal lucency correlates with a region of focal leakage on fluorescein angiography in eyes with central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging Retina 2015; 46: 832-836.

Iida T, Yannuzzi LA, Spaide RF et al. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 2003; 23: 1-7, quiz 137-138.

Cardillo Piccolino F, Lupidi M, Cagini C et al. Choroidal vascular reactivity in central serous chorioretinopathy. Invest Ophthalmol Vis Sci 2018; 59: 3897-3905.

Sahoo NK, Mishra SB, Iovino C et al. Optical coherence tomography angiography findings in cystoid macular degeneration associated with central serous chorioretinopathy. Br J Ophthalmol 2019; 103: 1615-1618.

Mrejen S, Balaratnasingam C, Kaden TR et al. Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmology 2019; 126: 576-588.

Spaide RF, Klancnik JM Jr. Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 2005; 112: 825-833.

Conrad R, Geiser F, Kleiman A et al. Temperament and character personality profile and illness-related stress in central serous chorioretinopathy. ScientificWorldJournal 2014; 2014: 631687.

Miki A, Kondo N, Yanagisawa S et al. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology 2014; 121: 1067-1072.

Negi A, Marmor M.F. Experimental serous retinal detachment and focal pigment epithelial damage. Arch Ophthalmol 1984; 102: 445-449.

Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 2013; 58: 103-126.

Spaide RF. Choroidal blood flow: review and potential explanation for the choroidal venous anatomy including the vortex vein system. Retina 2020; 40: 1851-1864.

Pang CE, Shah VP, Sarraf D, Freund KB. Ultra-widefield imaging with autofluorescence and indocyanine green angiography in central serous chorioretinopathy. Am J Ophthalmol 2014; 158: 362.e2-371.e2.

Brinks J, van Dijk EHC, Meijer OC et al. Choroidal arteriovenous anastomoses: a hypothesis for the pathogenesis of central serous chorioretinopathy and other pachychoroid disease spectrum abnormalities. Acta Ophthalmol 2022; 100: 946-959.

Imanaga N, Terao N, Nakamine S et al. Scleral thickness in central serous chorioretinopathy. Ophthalmol Retina 2021; 5: 285-291.

Fernández-Vigo JI, Moreno-Morillo FJ, Shi H et al. Assessment of the anterior scleral thickness in central serous chorioretinopathy patients by optical coherence tomography. Jpn J Ophthalmol 2021; 65: 769-776.

Sirakaya E, Duru Z, Kuçuk B, Duru N. Monocyte to high-density lipoprotein and neutrophil-to-lymphocyte ratios in patients with acute central serous chorioretinopathy. Indian J Ophthalmol 2020; 68: 854-858.

Zola M, Gobeaux C, Javorsky T et al. Galectin 3 and central serous chorioretinopathy: a promising new biomarker. Proc ARVO Annual Meeting 2021; 2021: 2197.

Bahadorani S, Maclean K, Wannamaker K et al. Treatment of central serous chorioretinopathy with topical NSAIDs. Clin Ophthalmol 2019; 13: 1543-1548.

Lehmann M, Bousquet E, Beydoun T, Behar-Cohen F. Pachychoroid: an inherited condition? Retina 2015; 35: 10-16.

Schubert C, Pryds A, Zeng S et al. Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Hum Mutat 2014; 35: 859-867.

Zhang X, Lim CZF, Chhablani J, Wong YM. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye Vis (Lond) 2023; 10: 33.

Potsaid B, Baumann B, Huang D et al. Ultrahigh speed 1050 nm swept source/fourier domain OCT retinal and anterior segment imaging at 100,000 to 400,000 axial scans per second. Opt Express 2010; 18: 20029-20048.

Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina 2013; 33: 1659-1672.

Gal-Or O, Dansingani KK, Sebrow D et al. Inner choroidal flow signal attenuation in pachychoroid disease: optical coherence tomography angiography. Retina 2018; 38: 1984-1992.

Burumcek E, Mudun A, Karacorlu S, Arslan MO. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology 1997; 104: 616-622.

Roca JA, Wu L, Fromow-Guerra J et al. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group. Br J Ophthalmol 2018; 102: 1696-1700.

Zeng M, Chen X, Song Y, Cai C. Subthreshold micropulse laser photocoagulation versus half-dose photodynamic therapy for acute central serous chorioretinopathy. BMC Ophthalmol 2022; 22: 110.

Yannuzzi LA, Slakter JS, Gross NE et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003; 23: 288-298.

van Dijk EHC, Fauser S, Breukink MB et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the place trial. Ophthalmology 2018; 125: 1547-1555.

Manayath GJ, Narendran V, Arora S et al. Graded subthreshold transpupillary thermotherapy for chronic central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 2012; 43: 284-290.

Peiretti E, Caminiti G, Serra R et al. Anti-vascular endothelial growth factor therapy versus photodynamic therapy in the treatment of choroidal neovascularization secondary to central serous chorioretinopathy. Retina 2018; 38: 1526-1532.

Duan J, Zhang Y, Zhang M. Efficacy and safety of the mineralocorticoid receptor antagonist treatment for central serous chorioretinopathy: a systematic review and meta-analysis. Eye (Lond) 2021; 35: 1102-1110.

Daugirdas SP, Bheemidi AR, Singh RP. Should we stop treating patients with eplerenone for chronic CSCR?: commentary on the VICI trial. Ophthalmic Surg Lasers Imaging Retina 2021; 52: 308-310.

Feenstra HMA, van Dijk EHC, van Rijssen TJ et al. Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3. Graefes Arch Clin Exp Ophthalmol 2023; 261: 659-668.

Salehi M, Wenick AS, Law HA et al. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev 2015; 2015: CD011841.

Gramajo AL, Marquez GE, Torres VE et al. Therapeutic benefit of melatonin in refractory central serous chorioretinopathy. Eye (Lond) 2015; 29: 1036-1045.

Lai TYY, Staurenghi G, Minerva Study Group et al. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the Minerva Study. Retina 2018; 38: 1464-1477.